Northern Oak Wealth Management Inc. Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Northern Oak Wealth Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 0.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 72,051 shares of the company’s stock after buying an additional 559 shares during the period. Johnson & Johnson accounts for approximately 1.4% of Northern Oak Wealth Management Inc.’s portfolio, making the stock its 23rd largest position. Northern Oak Wealth Management Inc.’s holdings in Johnson & Johnson were worth $9,322,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in JNJ. Virtus ETF Advisers LLC purchased a new position in Johnson & Johnson during the second quarter worth about $25,000. Krane Funds Advisors LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth $26,000. Financial Advantage Inc. acquired a new position in Johnson & Johnson during the 3rd quarter worth $28,000. Crewe Advisors LLC grew its holdings in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares in the last quarter. Finally, Eii Capital Management Inc. acquired a new position in Johnson & Johnson during the 3rd quarter worth $39,000. 72.25% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson stock opened at $133.00 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The company has a market cap of $343.25 billion, a PE ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. The company’s 50-day moving average is $130.83 and its two-hundred day moving average is $134.05.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the company posted $2.05 EPS. Research analysts forecast that Johnson & Johnson will post 8.65 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a yield of 2.86%. Johnson & Johnson’s payout ratio is 46.45%.

Several research analysts have recently commented on the stock. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Friday, October 11th. Bank of America reaffirmed a “hold” rating and issued a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a report on Tuesday, August 27th. Wells Fargo & Co decreased their price target on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a report on Wednesday, October 16th. Finally, Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $151.64.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is the cash asset ratio?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.